PLoS One:中国汉族女性乳腺癌促炎症因子多态性关联分析

2012-04-10 Deepblue 生物谷

目前,乳腺癌病因学的研究主要集中在免疫及炎症方面。已知促炎症因子IL-17A和IL-17F能够介导炎症和癌症的发生。为了评估在乳腺癌风险中IL-17A和IL-17F基因多态性的作用,来自中国哈尔滨医科大学肿瘤预防及治疗中心的庞达教授及其课题组在中国汉族女性中开展了一个乳腺癌病例对照研究。研究发现,IL-17A中的单核苷酸多态性与乳腺癌发生风险有关。相关文章发表在3月26日的美国《公共科学图书馆·综

目前,乳腺癌病因学的研究主要集中在免疫及炎症方面。已知促炎症因子IL-17A和IL-17F能够介导炎症和癌症的发生。为了评估在乳腺癌风险中IL-17A和IL-17F基因多态性的作用,来自中国哈尔滨医科大学肿瘤预防及治疗中心的庞达教授及其课题组在中国汉族女性中开展了一个乳腺癌病例对照研究。研究发现,IL-17A中的单核苷酸多态性与乳腺癌发生风险有关。相关文章发表在3月26日的美国《公共科学图书馆·综合》(PLoS One)上。

研究人员通过在IL-17A中发现的3个单核苷酸多态性(SNPs)(rs2275913, rs3819025 and rs3748067),以及在IL-17F中发现的5个SNPs(rs7771511, rs9382084, rs12203582, rs1266828和 rs763780),来确定在491个女性乳腺癌患者及502个健康个体中的单体型。通过SNaPshot技术研究者确定了基因型。而肺癌患者及健康个体的基因型分布差异则通过卡方检验被分析。

结果发现,对IL-17A中的rs2275913,AA基因型的频率高于控制组(P = 0.0016)。临床特征分析阐明了IL-17 SNPs与肿瘤蛋白53(P53)、黄体酮受体(PR)、人类表皮生长因子受体2 (Her-2)以及三阴状态(ER-/PR-/Her-2-)之间显著的联系。

除此之外,单体型分析表明了单体型Ars2275913Grs3819025Grs3748067的频率,位于IL-17A连锁不平衡模块,在患者中高于控制组(P = 0.0471)。

这项结果表明,IL-17A中的SNPs而不是IL-17F,与乳腺癌发生风险有关。总之,IL-17A及IL-17F的基因多态性可以提供有价值的信息,来推测中国女性乳腺癌的预后。(生物谷Deepblue编译)

doi: 10.1371/journal.pone.0034400
PMC:
PMID:

Association Analysis of IL-17A and IL-17F Polymorphisms in Chinese Han Women with Breast Cancer

Lihong Wang, Yongdong Jiang, Youxue Zhang, Yuwen Wang, Sunhui Huang, Zhihua Wang, Baoling Tian, Yue Yang, Wei Jiang, Da Pang.

Research into the etiology of breast cancer has recently focused on the role of the immunity and inflammation. The proinflammatory cytokines IL-17A and IL-17F can mediate inflammation and cancer. To evaluate the influences of IL-17A and IL-17F gene polymorphisms on the risk of sporadic breast cancer, a case-control study was conducted in Chinese Han women.We genotyped three single-nucleotide polymorphisms (SNPs) in IL-17A (rs2275913, rs3819025 and rs3748067) and five SNPs in IL-17F (rs7771511, rs9382084, rs12203582, rs1266828 and rs763780) to determine the haplotypes in 491 women with breast cancer and 502 healthy individuals.The genotypes were determined using the SNaPshot technique. The differences in the genotypic distribution between breast cancer patients and healthy controls were analyzed with the Chi-square test for trends.For rs2275913 in IL-17A, the frequency of the AA genotype was higher in patients than controls (P = 0.0016). The clinical features analysis demonstrated significant associations between IL-17 SNPs and tumor protein 53 (P53), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and triple-negative (ER-/PR-/Her-2-) status.In addition, the haplotype analysis indicated that the frequency of the haplotype Ars2275913Grs3819025Grs3748067, located in the IL-17A linkage disequilibrium (LD) block, was higher in patients than in controls (P = 0.0471 after correction for multiple testing).Our results suggested that SNPs in IL-17A but not IL-17F were associated with the risk of breast cancer.Both IL-17A and IL-17F gene polymorphisms may provide valuable information for predicting the prognosis of breast cancer in Chinese women.<.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1789398, encodeId=cf3b1e8939841, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Nov 29 22:47:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690032, encodeId=07ed169003285, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Thu Jul 12 20:47:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992015, encodeId=3b61199201574, content=<a href='/topic/show?id=92602e09206' target=_blank style='color:#2F92EE;'>#促炎症因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27092, encryptionId=92602e09206, topicName=促炎症因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Jun 15 21:47:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629176, encodeId=cec116291e62a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Apr 12 14:47:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1789398, encodeId=cf3b1e8939841, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Nov 29 22:47:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690032, encodeId=07ed169003285, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Thu Jul 12 20:47:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992015, encodeId=3b61199201574, content=<a href='/topic/show?id=92602e09206' target=_blank style='color:#2F92EE;'>#促炎症因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27092, encryptionId=92602e09206, topicName=促炎症因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Jun 15 21:47:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629176, encodeId=cec116291e62a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Apr 12 14:47:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1789398, encodeId=cf3b1e8939841, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Nov 29 22:47:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690032, encodeId=07ed169003285, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Thu Jul 12 20:47:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992015, encodeId=3b61199201574, content=<a href='/topic/show?id=92602e09206' target=_blank style='color:#2F92EE;'>#促炎症因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27092, encryptionId=92602e09206, topicName=促炎症因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Jun 15 21:47:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629176, encodeId=cec116291e62a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Apr 12 14:47:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1789398, encodeId=cf3b1e8939841, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu Nov 29 22:47:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690032, encodeId=07ed169003285, content=<a href='/topic/show?id=fb802e08724' target=_blank style='color:#2F92EE;'>#促炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27087, encryptionId=fb802e08724, topicName=促炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b3128951451, createdName=ms6127405442416114, createdTime=Thu Jul 12 20:47:00 CST 2012, time=2012-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992015, encodeId=3b61199201574, content=<a href='/topic/show?id=92602e09206' target=_blank style='color:#2F92EE;'>#促炎症因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27092, encryptionId=92602e09206, topicName=促炎症因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Jun 15 21:47:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629176, encodeId=cec116291e62a, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Apr 12 14:47:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-04-12 xzw120

相关资讯

Sci Transl Med:药物组合阻止侵袭性脑癌细胞的移动

3月28日,Sci Transl Med在线发表佐治亚理工学院研究人员的研究论文,研究人员发现一种叫做丙咪嗪蓝或IB的药物可阻止脑癌或神经胶质瘤的扩散。 当与常用抗癌药阿霉素合用时,IB可延长有病大鼠的生命,提示这一组合可能会在人体内成功地阻止脑胶质瘤的浸润。 传统的化疗几乎没有可能治疗脑胶质瘤这种通过入侵周围健康脑组织而快速生长的侵袭性的脑肿瘤。 大多数的脑胶质瘤患者会在诊断后几年死于该疾病。

Am J Pathol:调节胰腺癌细胞扩散的蛋白

伦敦Queen Mary大学研究人员发现一种调节胰腺癌细胞“粘性”的蛋白质,研究团队已经表明S100PBP蛋白能抑制蛋白酶Z的水平,蛋白酶Z使胰腺癌细胞具有粘性,使得它们能够扩散到周围环境中。 该项研究由英国慈善机构、胰腺癌症研究基金会(PCRF的)资助,发表于《美国病理学杂志》。 Queen Mary巴兹癌症研究所Tatjana Crnogorac-Jurcevic博士说:我们相信这些结果具

Theranostics:纳米粒子和交变磁场杀死小鼠体内癌细胞

佐治亚大学科学家们发现利用纳米粒子和交变磁场可以在半小时内杀死患头颈癌的小鼠体内肿瘤细胞,同时不伤害健康细胞。 相关研究结果发表在Theranostics杂志上,研究人员已经证实可以用磁性氧化铁纳米粒子诱导热疗法来治疗患这种类型癌症的老鼠。 该研究领导者、富兰克林艺术和科学学院物理学助理教授Qun Zhao说:“我们表明低浓度的纳米粒子就可以杀死癌细胞”。 世界各地的研究人员正在探索炽热的纳

PNAS:美开发新疗法 有望战胜7种癌症

日前,美国科学家研制出了一种能帮助人体免疫系统摧毁癌细胞的新型药物,对乳腺癌、肠癌、前列腺癌、子宫癌、脑癌、膀胱癌、肝癌等多种癌症都有疗效。此外前期研究表明,该药物还可用于治疗血癌(白血病)。研究人员表示,若能及早使用,该药物甚至可以完全治愈恶性肿瘤疾病,且副作用极小。 目前这种药物仅在小白鼠身上进行了试验,研究人员希望能在两年内开始临床试验。 据悉,新型药物的效力集中于一种大量存在于癌细胞表

JBC:科学家解开癌细胞死亡之谜的关键

由英国莱斯特大学领导的一个研究小组已证明某些肿瘤细胞对蛋白质P21特别敏感。这种蛋白质通常会迫使正常细胞与癌细胞停止分裂,但最近研究表明在某些情况下,P21也可以杀死癌细胞。 然而,科学家们一直不清楚这是如何发生的。 莱斯特大学生物化学系Salvador Macip研究员说:“如果我们可以利用P21的这种“杀伤力”,那么我们可以开发出旨在提高P21水平的癌症新疗法。 现在,英国莱斯特和加的夫

PLoS One:中国广州EBV相关胃癌LMP2A序列变化研究

潜伏膜蛋白2A (LMP2A),表达于大多数人类疱疹病毒(EBV)有关的恶性肿瘤,已经被证明是潜伏性感染及上皮细胞转化的主要诱因。 除此以外,它也可以作为基于CTL(cytotoxic T lymphocyte,细胞毒性T淋巴细胞)治疗EBV关联的恶性肿瘤的靶点。中国南部广州有鼻咽癌(NPC)地方性发病区,在目前的研究中,中山大学的邵春奎教授研究了该地区EBV相关的胃癌(EBVaGC)以及健康E